 we report net sales of $19 million in the first quarter of 2023, a 15% increase year-over-year and a slight decline versus the fourth quarter of 2022, which includes the gross-to-net headwinds. 
 we also report a net loss of $42.5 million for the first quarter of 2023, or $0.53 per basic and diluted share. 
 we continue to see strong momentum in our first line study, LOTIS-9, and we expect initial data from this study to be shared by the end of this year. 
 we also continue to see strong momentum in our third line, third line plus study of zyndranatib in unfit and frail patients not able to tolerate full doses of r-CHop. we expect to share initial data from this study in the first half of 2024. 
 we also continue to make progress on our pipeline including the combination of zyndranatib with rituximab in the second line plus setting and the combination of zyndranatib and bispecifics in the third line plus setting.    
 # 1_#1 _ # 1_#1 _    # 1_#1 _ =    # 1 1.25 in.125 in.25 in 